01-01-1970 12:00 AM | Source: SPA Securities Ltd
Key News Jubilant Foodworks, Shriram Transport & Zydus Cadila Ltd by SPA Securities
News By Tags | #3120 #572

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

Key News 

Jubilant Foodworks doubles its QSR target market with Popeyes tie-up

Jubilant Foodworks' latest tie-up to launch the Popeyes Restaurants in India will expand its food portfolio and increase the addressable market in the fast growing western quick service restaurant or QSR market. Popeyes Restaurants is the world’s third largest QSR chicken brand. The QSR chicken market size run by larger chains is estimated at around Rs 3,000 crore, in which KFC dominates controlling about two thirds of the market, estimates Emkay Research. Westlife Development (McDonald’s) recently ventured into this space in South India.

 

GoAir plans Rs 2,500-cr IPO early FY22; may file preliminary papers in Apr

Wadia group-owned GoAir plans to come out with a Rs 2,500 crore-initial share sale early next fiscal, according to sources. The no-frills airline has been working on expansion plans and an Initial Public Offer (IPO) will help in raising funds. In recent months, many companies have hit the capital market with their IPOs amid business activities slowly normalising after the pandemic blow. The carrier, which started operations in 2005, has been contemplating about going public in the last couple of years. The airline, which has also been witnessing frequent churns in the top management, could not come out with the IPO on a few occasions earlier.

 

Shriram Transport declares second dividend of Rs 6 per share for FY21

Shriram Transport Finance Company on Thursday said its board has declared a second interim dividend of Rs 6 per share for 2020-21. This is in addition to the first dividend of Rs 6 per share declared by the board on October 29, 2020 and paid to the eligible shareholders on November 26, Shriram Transport said in a regulatory filing. "The board of directors of the company at their meeting held on March 25, 2021 approved declaration of second interim dividend of Rs 6 per equity share of Rs 10 each fully paid up (60 per cent) for the financial year 2020-21," the company said. It said it has fixed April 6 as the record date for payment of the second interim dividend, subject to deduction of tax at source, to eligible shareholders.

 

Mukesh Ambani sees a 'tsunami of opportunities' for entrepreneurs

With the Indian Prime Minister Narendra Modi advocating a greater role for the private sector coupled with India's access to high end technology, Mukesh Ambani, Chairman and MD of Reliance Industries sees a "tsunami of opportunities" for young Indian entrepreneurs. Addressing the virtual 22nd Entrepreneur of the Year – India (EOY) 2020 Awards ceremony, Ambani said India should welcome Modi's initiative for a greater role for the private sector India's future development. Ambani said India now has the revolutionary power of new technologies to transform the economy. "Small, medium and big businesses have once-in-a-lifetime opportunity to meet the needs and aspirations of 1.3 billion people for good quality of life. We have the potential in the coming decades to be among top three economies of the world," Ambani said.

 

Zydus Cadila receives tentative nod from USFDA to market two HIV drugs

Zydus Cadila on Thursday said it has received a tentative nod from the US health regulator to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets used for controlling human immunodeficiency virus (HIV) infection, in America. The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ Ahmedabad, it added. The tablets are used with other HIV medications to help control HIV infection, Zydus Cadila said.

 

To Read Complete Report & Disclaimer Click Here

 

Above views are of the author and not of the website kindly read disclaimer